QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
Nominations now open for the 2026 NMI Measurement Awards
Until 20 May, the National Measurement Institute (NMI) is accepting nominations for the 2026 NMI...
Australia to begin treaty negotiations on association to Horizon Europe
To give Australian organisations access to the world's largest pooled research fund in 2027,...
Vaxxas partners with AI company Profenso to support quality assurance
A strategic partnership between Vaxxas and Profenso, an Australian AI company specialising in...
